pharmaceutical
Social Sciences
100%
expenditures
Social Sciences
95%
Japan
Medicine & Life Sciences
89%
incentive
Social Sciences
82%
risk sharing
Social Sciences
79%
R&D Performance
Business & Economics
75%
Health Expenditures
Business & Economics
61%
Price Risk
Business & Economics
60%
Nakamura, H. ,
Wakutsu, N. ,
Murayama, S. &
Suzuki, T. ,
2022 7月 ,
In: Journal of Clinical Pharmacology. 62 ,
7 ,
p. 847-854 8 p. 研究成果: Article › 査読
Drug Development
100%
Japan
87%
Pharmaceutical Preparations
43%
Clinical Trials
27%
Drug Approval
27%
Health Expenditures
100%
pharmaceutical
91%
expenditures
86%
Japan
81%
Motivation
79%
Health Expenditures
100%
Price Risk
98%
Reimbursement
91%
Incentives
91%
pharmaceutical
81%
Coulton, L. ,
Annemans, L. ,
Carter, R. ,
Herrera, M. B. ,
Thabrany, H. ,
Lim, J. ,
Lee, K. K. C. ,
Chen, W. ,
Chaiyakunapruk, N. ,
Chern, H. D. ,
Lee, T. J. ,
Nakamura, H. ,
Tarn, T. Y. H. &
Keskinaslan, A. ,
2012 11月 ,
In: Health Outcomes Research in Medicine. 3 ,
4 ,
p. e205-e219 研究成果: Article › 査読
risk sharing
100%
market
38%
Delivery of Health Care
31%
acceptance of agreement
24%
Aptitude
23%
R&D Performance
100%
Innovation Policy
75%
Open Innovation
70%
R&D Management
13%
Japanese Firms
11%